Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
Wieneke Dijk, Cédric Le May, Bertrand Cariou
Trends in Endocrinology and Metabolism (2018) Vol. 29, Iss. 6, pp. 420-434
Closed Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis
Weizhi Wang, Chao Liu, Jinque Luo, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 10, pp. 2119-2133
Closed Access | Times Cited: 17
Proprotein Convertase Subtilisin/Kexin Type 9
Chiara Macchi, Nicola Ferri, Cesare R. Sirtori, et al.
American Journal Of Pathology (2021) Vol. 191, Iss. 8, pp. 1385-1397
Open Access | Times Cited: 86
The PCSK9 revolution: Current status, controversies, and future directions
Bruce A. Warden, Sergio Fazio, Michael D. Shapiro
Trends in Cardiovascular Medicine (2019) Vol. 30, Iss. 3, pp. 179-185
Open Access | Times Cited: 84
The effect of artichoke on lipid profile: A review of possible mechanisms of action
Heitor O. Santos, Allain Amador Bueno, João Felipe Mota
Pharmacological Research (2018) Vol. 137, pp. 170-178
Closed Access | Times Cited: 71
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia
Yajnavalka Banerjee, Anca Pantea Stoian, Arrigo F.G. Cicero, et al.
Expert Opinion on Drug Safety (2021) Vol. 21, Iss. 1, pp. 9-20
Closed Access | Times Cited: 41
Remnant Lipoproteins Are Residual Risk Factor for Future Cardiovascular Events in Patients With Stable Coronary Artery Disease and On-Statin Low-Density Lipoprotein Cholesterol Levels <70 mg/dL
Yuki Fujihara, Takamitsu Nakamura, Takeo Horikoshi, et al.
Circulation Journal (2019) Vol. 83, Iss. 6, pp. 1302-1308
Open Access | Times Cited: 46
Association of hydroxytyrosol enriched olive oil with vascular function in chronic coronary disease
Ignatios Ikonomidis, Κ Katogiannis, C Chania, et al.
European Journal of Clinical Investigation (2023) Vol. 53, Iss. 7
Open Access | Times Cited: 15
Effect of alirocumab on postprandial hyperlipidaemia in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, cross‐over trial
Bertrand Cariou, An Thys, Arsênio Rodrigues Oliveira, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals
Chiara Macchi, Nicola Ferri, Chiara Favero, et al.
European Journal of Preventive Cardiology (2018) Vol. 26, Iss. 6, pp. 578-588
Open Access | Times Cited: 40
PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation
Ioanna Andreadou, Maria Tsoumani, Gemma Vilahur, et al.
Frontiers in Physiology (2020) Vol. 11
Open Access | Times Cited: 33
Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia
Amanda J. Hooper, Damon A. Bell, John R. Burnett
Expert Opinion on Pharmacotherapy (2024)
Closed Access | Times Cited: 4
Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population
Matthieu Wargny, Pierre‐Henri Ducluzeau, Jean‐Michel Petit, et al.
Atherosclerosis (2018) Vol. 278, pp. 82-90
Open Access | Times Cited: 35
Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
Helen M. Colhoun, Lawrence A. Leiter, Dirk Müller‐Wieland, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 25
Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control
Dragana Bojanin, Jelena Vekić, Tatjana Milenković, et al.
Atherosclerosis (2018) Vol. 280, pp. 14-20
Closed Access | Times Cited: 27
Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice
Damien Garçon, F. Moreau, Audrey Ayer, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2020) Vol. 40, Iss. 9, pp. 2084-2094
Open Access | Times Cited: 21
PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort
Juan Vicente-Valor, Xandra García‐González, Sara Ibáñez-García, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112519-112519
Open Access | Times Cited: 19
Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
Elisa Waldmann, WU Li-ya, Kristina Busygina, et al.
PLoS ONE (2022) Vol. 17, Iss. 3, pp. e0265838-e0265838
Open Access | Times Cited: 11
Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non‐small cell lung cancer
Mengqing Xie, Xin Yu, Xiangling Chu, et al.
Thoracic Cancer (2021) Vol. 13, Iss. 3, pp. 353-360
Open Access | Times Cited: 14
Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia
Wieneke Dijk, Bertrand Cariou
Diabetes Obesity and Metabolism (2019) Vol. 21, Iss. S1, pp. 39-51
Closed Access | Times Cited: 16
Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus
Laurenz T. Fischer, Daniel A. Hochfellner, Lisa Knoll, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 14
Prognostic impact of estimated remnant-like particle cholesterol in patients with differing glycometabolic status: an observational cohort study from China
Qi Zhao, Tingyu Zhang, Yujing Cheng, et al.
Lipids in Health and Disease (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 14
Role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in diabetic complications
Omonzejie E. Imaralu, Chandrakala Aluganti Narasimhulu, Pawan K. Singal, et al.
Canadian Journal of Physiology and Pharmacology (2023) Vol. 102, Iss. 01, pp. 14-25
Closed Access | Times Cited: 3
The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9
Fengyuan Lu, En Li, Xiaoyu Yang
Heliyon (2023) Vol. 9, Iss. 9, pp. e19371-e19371
Open Access | Times Cited: 3
Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance
Jean‐Philippe Drouin‐Chartier, André Tremblay, Jean‐Charles Hogue, et al.
Journal of Lipid Research (2018) Vol. 59, Iss. 8, pp. 1501-1509
Open Access | Times Cited: 8
Relationship of Zonulin with Serum PCSK9 Levels after a High Fat Load in a Population of Obese Subjects
María Molina‐Vega, Daniel Castellano‐Castillo, Lidia Sánchez‐Alcoholado, et al.
Biomolecules (2020) Vol. 10, Iss. 5, pp. 748-748
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top